J. Ferlay, E. Steliarova-foucher, J. Lortet-tieulent, S. Rosso, J. W. Coebergh et al., Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, issue.6, pp.1374-1403, 2013.

J. Taieb, T. André, and E. Auclin, Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives, Cancer Treatment Reviews, vol.75, pp.1-11, 2019.

F. Guyot, J. Faivre, S. Manfredi, B. Meny, C. Bonithon-kopp et al., Time trends in the treatment and survival of recurrences from colorectal cancer, Annals of Oncology, vol.16, issue.5, pp.756-761, 2005.

. Quasar-collaborative-group, Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study, The Lancet, vol.370, issue.9604, pp.2020-2029, 2007.

D. J. Sargent, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J. Clin. Oncol, vol.28, pp.3219-3226, 2010.

A. Figueredo, M. E. Coombes, and S. Mukherjee, Adjuvant Therapy for completely resected Stage II Colon Cancer, Cochrane Database of Systematic Reviews, p.5390, 2008.

C. Tournigand, T. André, F. Bonnetain, B. Chibaudel, G. Lledo et al., Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial, Journal of Clinical Oncology, vol.30, issue.27, pp.3353-3360, 2012.

, Vagina, AJCC Cancer Staging Manual, pp.387-393, 2010.

J. Roperch, R. Incitti, S. Forbin, F. Bard, H. Mansour et al., Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer, BMC Cancer, vol.13, issue.1, p.566, 2013.

S. Garrigou, G. Perkins, F. Garlan, C. Normand, A. Didelot et al., A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker, Clinical Chemistry, vol.62, issue.8, pp.1129-1139, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02295782

F. Garlan, P. Laurent-puig, D. Sefrioui, N. Siauve, A. Didelot et al., Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study), Clinical Cancer Research, vol.23, issue.18, pp.5416-5425, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02299521

J. B. Bachet, O. Bouché, J. Taieb, O. Dubreuil, M. L. Garcia et al., RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study, Annals of Oncology, vol.29, issue.5, pp.1211-1219, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02299512

J. Tie, Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer, Sci Transl Med, vol.8, pp.346-92, 2016.

J. Reinert, Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer, JAMA Oncol, 2019.

J. Taieb, V. Taly, D. Vernerey, C. Bourreau, J. Bennouna et al., Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration, Annals of Oncology, vol.30, p.v867, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02413130